Sales & Marketing News | pharmaphorum

News

Outlook finally claims FDA approval for AMD drug

After three knockbacks by the FDA, Outlook has finally pushed its therapy for age-related macular degeneration over the finish line in the US.

News

Ultomiris fail mars AZ's strong Q2 results

AstraZeneca has served up a robust set of interim results, leavened by strong sales of cancer drugs, but with some mixed pipeline news on the side.

News

EU clears AZ's SERD camizestrant, as FDA review drags on

AstraZeneca's new breast cancer therapy Etcamah claims landmark frontline approval in the EU, but its prospects in the US are less certain.

News

Nuvalent buy delivers new cancer approval for GSK

GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.

News

Takeda gets first OK for orexin narcolepsy drug, in China

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder narcolepsy.

News

Repligen builds in cell therapy with $1.5bn BioLife takeover

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

Outlook finally claims FDA approval for AMD drug

Ultomiris fail mars AZ's strong Q2 results

EU clears AZ's SERD camizestrant, as FDA review drags on

Nuvalent buy delivers new cancer approval for GSK

Takeda gets first OK for orexin narcolepsy drug, in China

Repligen builds in cell therapy with $1.5bn BioLife takeover

ESMO26: Lily's sofe-m ADC stakes a claim in ovarian cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks